secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2023-07-17T23:59:59+00:00
Accession:  0001193125-23-187698
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal completes NDA submission to FDA for resmetirom for NASH with liver fibrosis
--------------------------------------------------------------------------------

- Completed rolling NDA submission to FDA for resmetirom for NASH with liver fibrosis; priority review requested.
- Phase 3 MAESTRO-NASH met both primary liver biopsy endpoints: NASH resolution and fibrosis reduction.
- Resmetirom granted Breakthrough Therapy designation by FDA in April 2023.
- Two ongoing Phase 3 outcomes studies (MAESTRO-NASH-OUTCOMES, MAESTRO-NAFLD-OLE) to support full approval.
- No approved therapy exists for NASH; resmetirom targets key underlying causes as THR-β agonist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523187698/0001193125-23-187698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523187698/d508608d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-187698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer